Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 19 and up

SGLT2 inhibitor after cardioversion to help keep sinus rhythm in AF with HFpEF

Official title: Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial

Run by Samsung Medical Center · NCT07776054 · Data updated 2026-11-12

A large study will test whether starting an SGLT2 inhibitor after successful electrical cardioversion helps people with persistent atrial fibrillation and HFpEF stay in normal heart rhythm for at least a month.

Quick facts

PhasePhase 4
Study typeInterventional
Ages19 Years and up
SexAll
Enrollment200 (estimated)
SponsorSamsung Medical Center
Academic / other
Locations1 site (Seoul, Seoul)
StatusRecruiting
StartedFebruary 1, 2024
Main results expectedAugust 1, 2027
Study endsSeptember 1, 2027
Registry record updatedAugust 20, 2026
Trial IDNCT07776054 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with persistent AF and HFpEF (H2FPEF ≥6 or HFA-PEFF ≥5) who have achieved sinus rhythm after electrical cardioversion.

Probably not a fit

Patients who have contraindications to SGLT2 inhibitors, no tolerance for the study drug, or whose AF recurs very early may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center study randomizes 200 adults with persistent AF and HFpEF to receive an SGLT2 inhibitor or standard care after successful electrical cardioversion. Participants are stratified by AF duration and left atrial size and all receive anticoagulation and possible antiarrhythmic therapy per guidelines for at least one month. The primary outcome is recurrence of atrial tachyarrhythmia within 1 month, assessed by ECG or continuous monitoring. The trial uses an intention-to-treat analysis with a per-protocol sensitivity analysis and aims for about 90% power to detect a meaningful difference between groups.

Why it matters

Potential benefit: If successful, the approach could reduce early recurrence of atrial arrhythmia and improve overall rhythm control after cardioversion.

How similar studies have gone: Previous studies suggest SGLT2 inhibitors benefit heart failure broadly, but their effect on maintaining sinus rhythm after cardioversion is not well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥19 years
* Persistent atrial fibrillation
* H2FPEF score ≥6 or HFA-PEFF score ≥5
* Restoration of sinus rhythm after electrical cardioversion

Exclusion Criteria:

* Previous use of an SGLT2 inhibitor
* Intracardiac thrombus on transesophageal echocardiography
* Refusal to participate

Where it's running

  • Samsung Medical Center
    Seoul, Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.